Market Overview:
The global neuropathic pain drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of neuropathic pain, rising geriatric population, and growing demand for novel therapies. Based on type, the global neuropathic pain drugs market is segmented into tricyclic anti-depressants anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), capsaicin cream, local anaesthesia, opioids, steroids and others. Tricyclic anti-depressants anticonvulsants are expected to dominate the market in terms of revenue share during the forecast period owing to their high usage rates for treating various types of neuropathic pain conditions. Based on application, hospital pharmacies accounted for majority share of revenue in 2017 and is projected to maintain its dominance during the forecast period.
Product Definition:
Neuropathic pain is a type of chronic pain that is caused by damage to or dysfunction of the nerves. Neuropathic pain drugs are medications specifically used to treat neuropathic pain. They work by targeting the underlying cause of the nerve damage, which helps to reduce or eliminate the associated pain.
Tricyclic Anti-Depressants Anticonvulsants:
Tricyclic anti-depressants anticonvulsants are used for the treatment of depression and neuropathic pain. The drug class is also used to treat anxiety disorders, but this use is not approved by the FDA. Tricyclic drugs have been largely replaced by other classes of antidepressants due to side effects such as heart problems, drowsiness, blurred vision, dry mouth and sexual dysfunction that were observed in high doses.
Serotonin-Norepinephrine Reuptake Inhibitor:
A serotonin-noradrenaline reuptake inhibitor (SNRI) is a type of drug that inhibits the neuronal reabsorption of serotonin and noradrenaline. It has mainly two types, namely selective Serotonin Norepinephrine Reuptake Inhibitors (SNRI's) and non-selective SNRIs. The most commonly used drugs are duloxetine, venlafaxine, and milnacipran.
Application Insights:
Based on application, the global neuropathic pain drugs market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. The online pharmacy segment is projected to witness significant growth over the forecast period owing to various benefits offered such as convenience, flexibility of schedule and ability to order medicines without being present in-store. Additionally, customers are able to track their orders via email which provides additional assurance regarding product quality.
The other application segment includes applications that are not covered under any of the abovementioned categories such as surgical procedures involving nerves or spinal cord or peripheral nervous system surgery. This category also comprises patients who have undergone previous surgeries for trauma related injuries along with those suffering from diabetes mellitus type 1 and cancerous tumors growing in their bodies.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of neuropathic pain due to diabetes are some factors attributing to its largest share. In addition, rising awareness regarding treatment options is also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to growing patient pool suffering from chronic pain conditions coupled with improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in disposable income levels will also contribute toward this growth by driving demand for better quality pharmaceuticals that can be used for treating various diseases including neuropathic pain conditions.
The key companies involved in this space include Johnson & Johnson; Merck & Co., Inc.; Pfizer Inc.
Growth Factors:
- Increasing prevalence of neuropathic pain
- Rising geriatric population
- Growing demand for novel and effective therapies for neuropathic pain
- Technological advancements in the field of neurology and neuroscience
- Availability of government funding for research on neuropathic pain
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuropathic Pain Drugs Market Research Report
By Type
Tricyclic Anti-Depressants Anticonvulsants, Serotonin-Norepinephrine Reuptake Inhibitor, Capsaicin Cream, Local Anaesthesia, Opioids, Steroids, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline, Eli Lilly, Bristol-Myers Squibb, Biogen, Baxter Healthcare, Depomed
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
144
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Neuropathic Pain Drugs Market Report Segments:
The global Neuropathic Pain Drugs market is segmented on the basis of:
Types
Tricyclic Anti-Depressants Anticonvulsants, Serotonin-Norepinephrine Reuptake Inhibitor, Capsaicin Cream, Local Anaesthesia, Opioids, Steroids, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Johnson & Johnson
- Sanofi
- GlaxoSmithKline
- Eli Lilly
- Bristol-Myers Squibb
- Biogen
- Baxter Healthcare
- Depomed
Highlights of The Neuropathic Pain Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tricyclic Anti-Depressants Anticonvulsants
- Serotonin-Norepinephrine Reuptake Inhibitor
- Capsaicin Cream
- Local Anaesthesia
- Opioids
- Steroids
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuropathic Pain Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuropathic pain drugs are medications that are used to treat neuropathic pain. Neuropathic pain is a type of chronic pain that is caused by damage to the nerves. These drugs work by blocking nerve signals and reducing the amount ofpain felt.
Some of the major companies in the neuropathic pain drugs market are Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline, Eli Lilly, Bristol-Myers Squibb, Biogen, Baxter Healthcare, Depomed.
The neuropathic pain drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neuropathic Pain Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neuropathic Pain Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neuropathic Pain Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neuropathic Pain Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neuropathic Pain Drugs Market Size & Forecast, 2020-2028
4.5.1 Neuropathic Pain Drugs Market Size and Y-o-Y Growth
4.5.2 Neuropathic Pain Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tricyclic Anti-Depressants Anticonvulsants
5.2.2 Serotonin-Norepinephrine Reuptake Inhibitor
5.2.3 Capsaicin Cream
5.2.4 Local Anaesthesia
5.2.5 Opioids
5.2.6 Steroids
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neuropathic Pain Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neuropathic Pain Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tricyclic Anti-Depressants Anticonvulsants
9.6.2 Serotonin-Norepinephrine Reuptake Inhibitor
9.6.3 Capsaicin Cream
9.6.4 Local Anaesthesia
9.6.5 Opioids
9.6.6 Steroids
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tricyclic Anti-Depressants Anticonvulsants
10.6.2 Serotonin-Norepinephrine Reuptake Inhibitor
10.6.3 Capsaicin Cream
10.6.4 Local Anaesthesia
10.6.5 Opioids
10.6.6 Steroids
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tricyclic Anti-Depressants Anticonvulsants
11.6.2 Serotonin-Norepinephrine Reuptake Inhibitor
11.6.3 Capsaicin Cream
11.6.4 Local Anaesthesia
11.6.5 Opioids
11.6.6 Steroids
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tricyclic Anti-Depressants Anticonvulsants
12.6.2 Serotonin-Norepinephrine Reuptake Inhibitor
12.6.3 Capsaicin Cream
12.6.4 Local Anaesthesia
12.6.5 Opioids
12.6.6 Steroids
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tricyclic Anti-Depressants Anticonvulsants
13.6.2 Serotonin-Norepinephrine Reuptake Inhibitor
13.6.3 Capsaicin Cream
13.6.4 Local Anaesthesia
13.6.5 Opioids
13.6.6 Steroids
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neuropathic Pain Drugs Market: Competitive Dashboard
14.2 Global Neuropathic Pain Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Johnson & Johnson
14.3.3 Sanofi
14.3.4 GlaxoSmithKline
14.3.5 Eli Lilly
14.3.6 Bristol-Myers Squibb
14.3.7 Biogen
14.3.8 Baxter Healthcare
14.3.9 Depomed
